Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- US Aims for Lifting of Ban on Mixed Care: Prof. Murakami of Yamagata University
July 22, 2013
- South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020
July 19, 2013
- CSIMC Begins Full-Scale Discussions on FY2014 NHI Price Revision; Generics as Well as Long-Listed Original Drugs May Face Further Price Cuts
July 19, 2013
- eCTD Progresses to Step 4 at ICH in Brussels
July 18, 2013
- 2nd Committee on Drugs to Discuss Approval for Asthma Treatment Flutiform on July 26
July 17, 2013
- MHLW, US FDA to Exchange Information with a View to Standardizing Review Guidelines for Regenerative Medicines
July 17, 2013
- Health Ministry to Set Up Committee on Diovan Studies, Compile Preventive Measures for Clinical Data Manipulation
July 16, 2013
- MHLW Presses Kyoto Prefectural University of Medicine to Carry on Diovan Probe
July 16, 2013
- Health Ministry Requests Revisions of Precautions for Invega Tablets, Other Drugs
July 12, 2013
- Generic Substitution Reduced Drug Expenditure by 16.3 Billion Yen Over Last 4 Years: Kyokai Kenpo
July 11, 2013
- TPP Member States to Brief Japan on Drug Pricing, Intellectual Property on July 25
July 9, 2013
- Dr Nakashima of PMDA Proposes Freeze on NHI Prices of Generics for Which Companies Take Steps to Ensure Stable Supplies
July 9, 2013
- Campaign Starts for Upper House Race, Organized Votes Eyed
July 8, 2013
- Notification Calls for Cooperation to Prevent Local Shortages of Rubella Vaccine
July 5, 2013
- Health Ministry to Give Guidance to Parties Suspected of Data Manipulation in Anti-Obesity Drug Clinical Study
July 4, 2013
- Expiration Date for Tamiflu Capsules Extended from 7 to 10 Years
July 3, 2013
- Notification Calls for Simultaneous Filing of Applications for Companion Diagnostics and Drugs
July 3, 2013
- Deputy Mayor of Ikoma Proposes Reduction of Dispensing Fees for Pharmacies With Low Generic Dispensing Rates
July 2, 2013
- MHLW Project Stops Short of Setting Generic Evaluation Criteria
July 1, 2013
- Price Settlement Rate for Chain Pharmacies Fell Below 50% in FY2012: Survey
July 1, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…